文献速递慢性肾脏病血液净化与透析

达普司他对比传统红细胞生成刺激剂治疗期间癌症安全性事件分析——ASCEND-ND与ASCEND-D试验的事后分析

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本文对ASCEND-ND(3872例)和ASCEND-D(2964例)进行事后分析,评估达普司他与传统红细胞生成刺激剂(ESAs)治疗期间癌症相关不良事件风险。ASCEND-ND中预设的on-treatment分析显示,风险估计取决于末次给药后的随访时长:末次给药+1天时HR 1.50(95%CI 1.04, 2.15),末次给药+给药间隔时HR 1.12(95%CI 0.81, 1.56),研究结束时HR 1.04(95%CI 0.77, 1.40);ASCEND-D中所有模型均未观察到癌症相关不良事件风险增加。作者认为预设on-treatment分析因优先少计达贝泊汀组事件而导致偏倚风险估计。

要点

  • ASCEND-ND中达普司他对比达贝泊汀的癌症相关不良事件风险随随访时长变化:末次给药+1天HR 1.50(95%CI 1.04, 2.15),末次给药+给药间隔HR 1.12(95%CI 0.81, 1.56),研究结束HR 1.04(95%CI 0.77, 1.40)。
  • ASCEND-D中所有分析模型均未观察到达普司他组癌症相关不良事件风险增加。
  • 作者认为预设on-treatment分析因优先少计达贝泊汀组事件而产生偏倚风险估计,延长随访或考虑给药间隔后效应估计趋于无效。

核心结论

  • 预设on-treatment分析在ASCEND-ND中因优先少计达贝泊汀组事件而似乎产生偏倚的风险估计;考虑较长达贝泊汀给药间隔或延长随访后,效应估计趋于无效,与ASCEND-D结果相似。

研究设计与样本

  • ASCEND-ND(NCT02876835)随机分配3872例患者至达普司他或达贝泊汀;ASCEND-D(NCT02879305)随机分配2964例患者至达普司他或传统红细胞生成刺激剂(ESAs)。
  • 两项研究中ESA对照药使用不同给药间隔(每周3次、每周1次、每2周或每4周)。
  • 预设on-treatment方法检查至末次给药日期+1天的癌症不良事件相对风险;因组间给药间隔不同,采用Cox模型按不同随访期(末次给药日删失、末次给药日+给药间隔删失或研究结束时删失)估计达普司他效应。

主要发现

  • ASCEND-ND中达普司他对比达贝泊汀的癌症相关不良事件安全性取决于末次给药后的随访时长:研究结束时HR 1.04(95%CI 0.77, 1.40),末次给药+给药间隔HR 1.12(95%CI 0.81, 1.56),末次给药+1天HR 1.50(95%CI 1.04, 2.15)。
  • ASCEND-D中所有检查的模型均未观察到癌症相关不良事件风险增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not observed in dialysis patients in ASCEND-D (NCT02879305). METHODS: ASCEND-ND randomized 3872 patients to daprodustat or darbepoetin. ASCEND-D randomized 2964 patients to daprodustat or conventional erythropoiesis-stimulating agents (ESAs). In both studies ESA comparators used different dosing intervals (3/week, 1/week, every 2 or every 4 weeks). The prespecified on-treatment approach examined relative risks for cancer AEs up to the last dose date + 1 day. In these analyses, owing to different dosing intervals between arms, Cox models were used to estimate the daprodustat effect by various follow-up periods (censoring at last dose date, last dose date + dosing intervals, or end of study). RESULTS: In ASCEND-ND, the safety of daprodustat vs darbepoetin on cancer-related AEs depended on the duration of follow-up after last dose date: hazard ratio (HR) 1.04 [95% confidence interval (CI) 0.77, 1.40] at end of study [HR 1.12 (95% CI 0.81, 1.56) for last dose date + dosing interval; HR 1.50 (95% CI 1.04, 2.15) for last dose date + 1 day]. In ASCEND-D, no excess risk of cancer-related AEs was observed with any model examined. CONCLUSIONS: Prespecified on-treatment analyses for cancer-related AEs appeared to result in biased risk estimates in ASCEND-ND by preferentially under-counting events from patients assigned to darbepoetin. Analyses accounting for longer darbepoetin dosing intervals, or extending follow-up, resulted in attenuation of effect estimates towards neutrality, similar to ASCEND-D, where ESA comparator dosing intervals are closer to daprodustat. TRIAL REGISTRATION: The ASCEND-ND trial is registered with ClinicalTrials.gov (NCT02876835); the ASCEND-D trial is registered with ClinicalTrials.gov (NCT02879305).

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Singh AK, McCausland FR, Claggett BL, et al. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023. PMID: 36565721. doi:10.1093/ndt/gfac342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。